Stomach cancer primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 19: Line 19:


== Prevention Through Screening ==
== Prevention Through Screening ==
* In countries with a high incidence of gastric cancer such as east Asia countries, universal [[Screening (medicine)|screening]] is recommended.
* In countries with a high incidence of gastric cancer such as east Asia countries, universal [[Screening (medicine)|screening]] is recommended  
* Japan has a high [[incidence]] of gastric cancer; therefore annual [[Screening (medicine)|screening]] via double contrast [[Barium follow-through|barium radiography]] and photofluorography every year or [[upper endoscopy]] every two to three years <ref name="pmid16232204">{{cite journal |vauthors=Ohata H, Oka M, Yanaoka K, Shimizu Y, Mukoubayashi C, Mugitani K, Iwane M, Nakamura H, Tamai H, Arii K, Nakata H, Yoshimura N, Takeshita T, Miki K, Mohara O, Ichinose M |title=Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography |journal=Cancer Sci. |volume=96 |issue=10 |pages=713–20 |date=October 2005 |pmid=16232204 |doi=10.1111/j.1349-7006.2005.00098.x |url=}}</ref>
* Japan has a high [[incidence]] of gastric cancer; therefore annual [[Screening (medicine)|screening]] via double contrast [[Barium follow-through|barium radiography]] and photofluorography every year or [[upper endoscopy]] every two to three years <ref name="pmid16232204">{{cite journal |vauthors=Ohata H, Oka M, Yanaoka K, Shimizu Y, Mukoubayashi C, Mugitani K, Iwane M, Nakamura H, Tamai H, Arii K, Nakata H, Yoshimura N, Takeshita T, Miki K, Mohara O, Ichinose M |title=Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography |journal=Cancer Sci. |volume=96 |issue=10 |pages=713–20 |date=October 2005 |pmid=16232204 |doi=10.1111/j.1349-7006.2005.00098.x |url=}}</ref>
* [[Screening (medicine)|Screening]] interval is recommended to be every two years but may be extended to a three-year interval without significant difference in effect<ref name="pmid16232204">{{cite journal |vauthors=Ohata H, Oka M, Yanaoka K, Shimizu Y, Mukoubayashi C, Mugitani K, Iwane M, Nakamura H, Tamai H, Arii K, Nakata H, Yoshimura N, Takeshita T, Miki K, Mohara O, Ichinose M |title=Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography |journal=Cancer Sci. |volume=96 |issue=10 |pages=713–20 |date=October 2005 |pmid=16232204 |doi=10.1111/j.1349-7006.2005.00098.x |url=}}</ref>
* [[Screening (medicine)|Screening]] interval is recommended to be every two years but may be extended to a three-year interval without significant difference in effect<ref name="pmid16232204">{{cite journal |vauthors=Ohata H, Oka M, Yanaoka K, Shimizu Y, Mukoubayashi C, Mugitani K, Iwane M, Nakamura H, Tamai H, Arii K, Nakata H, Yoshimura N, Takeshita T, Miki K, Mohara O, Ichinose M |title=Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography |journal=Cancer Sci. |volume=96 |issue=10 |pages=713–20 |date=October 2005 |pmid=16232204 |doi=10.1111/j.1349-7006.2005.00098.x |url=}}</ref>


== Prevention of Hereditary Cancer  ==
== Prevention of Hereditary Cancer  ==
=== '''Screening''' ===
* In areas of low gastric cancer [[incidence]], [[Screening (medicine)|screening]] for gastric cancer with [[upper endoscopy]] should be reserved for specific high-risk subgroups
* Individuals at increased risk for gastric cancer include those with the following:
** Gastric [[adenomas]]
** [[Pernicious anemia]]
** Gastric intestinal [[metaplasia]]
** [[Familial adenomatous polyposis]]
** [[Lynch syndrome]]
** [[Peutz-Jeghers syndrome]]
** [[Juvenile polyposis syndrome]]


=== Prevention ===
=== Prevention ===
Line 48: Line 36:
* Patients who are older than 75 years should not undergo such a procedure, as their mortality from the procedure outweighs their [[mortality]] from gastric cancer.  
* Patients who are older than 75 years should not undergo such a procedure, as their mortality from the procedure outweighs their [[mortality]] from gastric cancer.  
* Decisions should be individualized based upon their comorbidities and the age of gastric cancer onset in their respective kindred.<ref name="pmid11443625">{{cite journal| author=Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ et al.| title=Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? | journal=Cancer | year= 2001 | volume= 92 | issue= 1 | pages= 181-7 | pmid=11443625 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11443625  }}</ref>
* Decisions should be individualized based upon their comorbidities and the age of gastric cancer onset in their respective kindred.<ref name="pmid11443625">{{cite journal| author=Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ et al.| title=Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? | journal=Cancer | year= 2001 | volume= 92 | issue= 1 | pages= 181-7 | pmid=11443625 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11443625  }}</ref>
== Gastric Polyps ==
* [[Polypectomy]] should be performed for all known [[neoplastic]] [[polyps]] and for all [[polyps]] ≥1 cm in diameter, as biopsies alone cannot exclude foci of high-grade [[dysplasia]] or early gastric cancer.
* In patients with multiple [[polyps]], the largest [[polyp]] should be excised and representative [[biopsies]] should be obtained from the remaining [[polyps]].
* [[Fundic gland polyposis|Fundic gland polyps]] are associated with a low risk of progression to cancer.
* Small proximal gastric [[polyps]] should be biopsied in patients with [[familial adenomatous polyposis]] ([[FAP]]) to confirm their [[histology]].
* Large or irregular appearing [[polyps]] should be [[Biopsy|biopsied]] or resected completely to assess for [[dysplasia]].
* Low-grade [[dysplasia]] is common in [[Fundic gland polyposis|fundic gland polyps]], but surgery should be reserved for high-grade [[dysplasia]] or [[cancer]].
* [[Antrum|Antral]] [[polyps]] are usually [[adenomas]] and should be completely resected [[Endoscopy|endoscopically]] if possible. ?
=== Hyperplastic polyps ===
* [[Hyperplastic polyp|Hyperplastic polyps]] occur in association with ''[[H. pylori]]-''related [[atrophic gastritis]]. 
* Surveillance with [[upper endoscopy]] should be performed based on the [[risk factors]] for gastric cancer one year after initial resection of [[Familial adenomatous polyposis|adenomatous gastric polyps]].
* In individuals at high risk for gastric cancer, surveillance is continued long life.
== Juvenile Polyposis Syndrome ==
* [[Screening (medicine)|Screening]] the [[upper gastrointestinal tract]] with [[upper endoscopy]] starting at the age of 12 years.
* If [[Polyp|polyps]] are detected, [[upper endoscopy]] should be repeated annually.
* In the absence of [[upper gastrointestinal tract]] [[polyps]], [[upper endoscopy]] can be performed every two to three years.
== Lynch Syndrome ==
* Individuals with a [[germline mutation]] in the [[DNA mismatch repair]] MMR or ''EPCAM'' [[genes]] have a definitive diagnosis of [[Lynch syndrome]] and should undergo [[Screening (medicine)|screening]] for [[Lynch syndrome]] associated [[cancers]].
* Extent of [[Screening (medicine)|screening]] in these individuals can be individualized based on their personal and family [[cancer]] history and evidence of [[microsatellite instability]] on [[tumor]] testing.
* Individuals at risk for [[Lynch syndrome]] include:
** Individuals in families meeting Amsterdam I or II criteria or revised Bethesda guidelines
* [[Endometrial cancer]] prior to age 50 years
* First-degree relative of those with known MMR/''EPCAM'' [[gene mutation]]
* Individuals with >5 percent chance of an MMR [[gene]] [[mutation]]


==References==
==References==

Revision as of 19:03, 25 January 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2] Mohammed Abdelwahed M.D[3]

Stomach cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Stomach Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Endoscopy and Biopsy

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Stomach cancer primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Stomach cancer primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stomach cancer primary prevention

CDC on Stomach cancer primary prevention

Stomach cancer primary prevention in the news

Blogs on Stomach cancer primary prevention

Directions to Hospitals Treating Stomach cancer

Risk calculators and risk factors for Stomach cancer primary prevention

Overview

Effective measures for the primary prevention of stomach cancer include smoking cessation, eradication of Helicobacter pylori infection, and having a balanced diet rich in fruits and vegetables. In areas of low gastric cancer incidence, screening for gastric cancer with upper endoscopy should be reserved for specific high-risk subgroups. Individuals at increased risk for gastric cancer include; gastric adenomas, pernicious anemia, gastric intestinal metaplasia, familial adenomatous polyposis, Lynch syndrome, Peutz-Jeghers syndrome, Juvenile polyposis syndrome.

Primary prevention

Lifestyle modifications

Lifestyle modifications include following:[1]

  • Dietary modification is an important approach to control gastric cancer. There is a link between physical inactivity and obesity to many types of cancer.
  • Diet with low consumption of red meat, high in fruits and vegetables may have a protective effect against many cancers.
  • The World Health Assembly adopted the WHO Global Strategy on Diet, Physical Activity, and Health, in May 2004 to reduce deaths and diseases.

H.pylori eradication

Prevention Through Screening

  • In countries with a high incidence of gastric cancer such as east Asia countries, universal screening is recommended
  • Japan has a high incidence of gastric cancer; therefore annual screening via double contrast barium radiography and photofluorography every year or upper endoscopy every two to three years [3]
  • Screening interval is recommended to be every two years but may be extended to a three-year interval without significant difference in effect[3]

Prevention of Hereditary Cancer

Prevention

  • For patients with a CDH1 mutation but who are not from an HDGC family, individualized evaluation at an experienced center before prophylactic total gastrectomy is recomended.[6]
  • Prophylactic gastrectomy is often advised between age 20 and 30.
  • Some suggest timing total gastrectomy in CDH1 mutation carriers at an age that is five years younger than the youngest family member who developed gastric cancer.[7]
  • Older patients are less likely to benefit from a prophylactic gastrectomy than younger patients because of a shorter life-expectancy and a higher perioperative risk.[5]
  • Patients who are older than 75 years should not undergo such a procedure, as their mortality from the procedure outweighs their mortality from gastric cancer.
  • Decisions should be individualized based upon their comorbidities and the age of gastric cancer onset in their respective kindred.[8]

References

  1. 1.0 1.1 Park JY, von Karsa L, Herrero R (November 2014). "Prevention strategies for gastric cancer: a global perspective". Clin Endosc. 47 (6): 478–89. doi:10.5946/ce.2014.47.6.478. PMC 4260094. PMID 25505712.
  2. García Martín R, Matía Cubillo Á (May 2016). "[INFLUENCE OF DIET IN PRIMARY PREVENTION OF GASTRIC CANCER, IN PATIENTS INFECTED WITH HELICOBACTER PYLORI]". Rev Enferm (in Spanish; Castilian). 39 (5): 33–8. PMID 27405145.
  3. 3.0 3.1 Ohata H, Oka M, Yanaoka K, Shimizu Y, Mukoubayashi C, Mugitani K, Iwane M, Nakamura H, Tamai H, Arii K, Nakata H, Yoshimura N, Takeshita T, Miki K, Mohara O, Ichinose M (October 2005). "Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography". Cancer Sci. 96 (10): 713–20. doi:10.1111/j.1349-7006.2005.00098.x. PMID 16232204.
  4. Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S; et al. (1999). "Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation". Am J Pathol. 155 (2): 337–42. doi:10.1016/S0002-9440(10)65129-2. PMC 1866861. PMID 10433926.
  5. 5.0 5.1 Abreu E (1997). "[Primary prevention and detection of gastric cancer]". Cad Saude Publica (in Portuguese). 13 Suppl 1: 105–108. PMID 10886930. Vancouver style error: initials (help)
  6. Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage Consortium (2001). "Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families". Gastroenterology. 121 (6): 1348–53. PMID 11729114.
  7. Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG; et al. (2007). "CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer". Ann Surg. 245 (6): 873–9. doi:10.1097/01.sla.0000254370.29893.e4. PMC 1876967. PMID 17522512.
  8. Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ; et al. (2001). "Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated?". Cancer. 92 (1): 181–7. PMID 11443625.

Template:WH Template:WS